La Tour Eiffel par nuit
Paris, France: It’s the dog days of summer and my reading stack of interesting science and cancer research papers is particularly high at the moment despite reading voraciously over the last few weeks…
So much excellent research keeps on piling up as fast as one can get through it.
It’s beginning to feel like Ravel’s Bolero…
Still, there’s one particular batch of important papers that draws together some interesting findings in an area we have been following for a little while now and these data most certainly advance the field in more ways than one.
Subscribers can log-in below to read our latest insights or you can sign up via the blue box to learn more…
At the recent scientific meeting to celebrate the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (#CIML40), Professor Ton Schumacher from the Netherlands Cancer Institute gave an informative presentation on “T cell recognition and tumor resistance in human cancer.”
Picture Credit: ATGC Partners
Schumacher started his talk at CIML by saying, “I guess by now I should consider myself a cancer immunologist…”
Cancer immunologist ‘wannabes’ should take note of the level of expertise required to be considered one!
He is one of the co-founders of Neon Therapeutics and a leading researcher into antigen-specific T cell immunity.
Several companies are seeking to develop personalized cancer vaccines against patient-specific neoantigens.
We previously wrote about the approach Neon Therapeutics is following based on expert interviews with the interim CEO Cary Pfeffer and scientific co-founder Dr Cathy Wu.
Yesterday the field heated up when it was announced that German biotech BioNTech AG had entered a strategic collaboration with Genentech to develop individualized mRNA cancer therapies (Sept 20, 2016 press release).
This post continues the BSB mini-series on targeting neoantigens that we started last month. Do check out previous posts if you missed them:
After his #CIML40 presentation, Prof Schumacher kindly spoke to BSB.
Subscribers can login to read more or you can purchase access below.